FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297013991> ?p ?o ?g. }

• W4297013991 endingPage "100226" @default.
• W4297013991 startingPage "100226" @default.
• W4297013991 abstract "PurposeTo identify baseline ocular and systemic factors associated with central subfield thickness (CST) fluctuations in patients with diabetic macular edema (DME) using data from Diabetic Retinopathy Clinical Research Protocols T and V.DesignPost hoc analysis of clinical trial databases.SubjectsPatients in Protocols T and V.MethodsThe standard deviation (SD) of all recorded CSTs for each patient during each Protocol’s study period was calculated. The CST SD (corresponding to CST fluctuations) for each patient was analyzed against baseline ocular and systemic factors using linear regression analyses. Each Protocol was analyzed separately.Main Outcome MeasuresFactors associated with CST fluctuations.ResultsA total of 1197 eyes of 1197 subjects were included. In Protocol T (559 eyes, mean CST SD was 56.4 ± 35.1 microns), using multivariate linear regression analysis, baseline urine albumin/creatine ratio (for every 1000 mg/g, CST point estimate 3.50, 95% confidence interval [CI] 0.58 to 6.43, P = 0.0190), and baseline CST (for every 10 microns, 0.87, 95% CI 0.58 to 1.16, P < 0.0001) were positively associated with CST fluctuations. Baseline visual acuity (for every 10 ETDRS letters, −9.52, 95% CI −11.89 to −7.15, P < 0.0001) was negatively associated with CST fluctuations. In Protocol V (638 eyes, mean CST SD 36.6 ± 28.4 microns), gender (female, 2.18, 95% CI 0.30 to 4.06, P = 0.0227), baseline CST (for every 10 microns, 2.51, 95% CI 2.21 to 2.82, P < 0.0001), systolic blood pressure (for every 1 mm of mercury, 0.11, 95% CI 0.01 to 0.21, P = 0.0261), and observation with deferred anti-VEGF injections (5.04, 95% CI 2.51 to 7.58, P < 0.0001) were positively associated with CST fluctuations. Type 2 diabetes (−7.37, 95% CI −13.64 to −1.11, P = 0.0209) and prompt anti-VEGF injections (−6.51, 95% CI −9.07 to −3.96, P < 0.0001) were negatively associated with CST fluctuations.ConclusionsWorse visual acuity at baseline, baseline renal disease, hypertension, female gender, type 1 diabetes, and delayed anti-VEGF treatment may be associated with increased CST fluctuations in patients with DME. Addressing these parameters may limit CST fluctuations and help identify patients requiring more frequent monitoring or treatment. To identify baseline ocular and systemic factors associated with central subfield thickness (CST) fluctuations in patients with diabetic macular edema (DME) using data from Diabetic Retinopathy Clinical Research Protocols T and V. Post hoc analysis of clinical trial databases. Patients in Protocols T and V. The standard deviation (SD) of all recorded CSTs for each patient during each Protocol’s study period was calculated. The CST SD (corresponding to CST fluctuations) for each patient was analyzed against baseline ocular and systemic factors using linear regression analyses. Each Protocol was analyzed separately. Factors associated with CST fluctuations. A total of 1197 eyes of 1197 subjects were included. In Protocol T (559 eyes, mean CST SD was 56.4 ± 35.1 microns), using multivariate linear regression analysis, baseline urine albumin/creatine ratio (for every 1000 mg/g, CST point estimate 3.50, 95% confidence interval [CI] 0.58 to 6.43, P = 0.0190), and baseline CST (for every 10 microns, 0.87, 95% CI 0.58 to 1.16, P < 0.0001) were positively associated with CST fluctuations. Baseline visual acuity (for every 10 ETDRS letters, −9.52, 95% CI −11.89 to −7.15, P < 0.0001) was negatively associated with CST fluctuations. In Protocol V (638 eyes, mean CST SD 36.6 ± 28.4 microns), gender (female, 2.18, 95% CI 0.30 to 4.06, P = 0.0227), baseline CST (for every 10 microns, 2.51, 95% CI 2.21 to 2.82, P < 0.0001), systolic blood pressure (for every 1 mm of mercury, 0.11, 95% CI 0.01 to 0.21, P = 0.0261), and observation with deferred anti-VEGF injections (5.04, 95% CI 2.51 to 7.58, P < 0.0001) were positively associated with CST fluctuations. Type 2 diabetes (−7.37, 95% CI −13.64 to −1.11, P = 0.0209) and prompt anti-VEGF injections (−6.51, 95% CI −9.07 to −3.96, P < 0.0001) were negatively associated with CST fluctuations. Worse visual acuity at baseline, baseline renal disease, hypertension, female gender, type 1 diabetes, and delayed anti-VEGF treatment may be associated with increased CST fluctuations in patients with DME. Addressing these parameters may limit CST fluctuations and help identify patients requiring more frequent monitoring or treatment." @default.
• W4297013991 created "2022-09-25" @default.
• W4297013991 creator A5003286037 @default.
• W4297013991 creator A5027369181 @default.
• W4297013991 creator A5031536941 @default.
• W4297013991 creator A5034114376 @default.
• W4297013991 creator A5035588405 @default.
• W4297013991 creator A5039099781 @default.
• W4297013991 creator A5050143121 @default.
• W4297013991 creator A5061263607 @default.
• W4297013991 creator A5064919549 @default.
• W4297013991 creator A5076869667 @default.
• W4297013991 date "2023-03-01" @default.
• W4297013991 modified "2023-09-30" @default.
• W4297013991 title "Factors Associated with Fluctuations in Central Subfield Thickness in Patients with Diabetic Macular Edema Using Diabetic Retinopathy Clinical Research Protocols T and V" @default.
• W4297013991 cites W13715332 @default.
• W4297013991 cites W1519861371 @default.
• W4297013991 cites W1574902248 @default.
• W4297013991 cites W1786299986 @default.
• W4297013991 cites W1971041643 @default.
• W4297013991 cites W1997167786 @default.
• W4297013991 cites W2000061236 @default.
• W4297013991 cites W2001649198 @default.
• W4297013991 cites W2013921064 @default.
• W4297013991 cites W2027769879 @default.
• W4297013991 cites W2038309299 @default.
• W4297013991 cites W2051774146 @default.
• W4297013991 cites W2060207361 @default.
• W4297013991 cites W2061086767 @default.
• W4297013991 cites W2062005421 @default.
• W4297013991 cites W2075206985 @default.
• W4297013991 cites W2091707840 @default.
• W4297013991 cites W2114980899 @default.
• W4297013991 cites W2185429893 @default.
• W4297013991 cites W2515796858 @default.
• W4297013991 cites W2619703590 @default.
• W4297013991 cites W2943809429 @default.
• W4297013991 cites W2947484293 @default.
• W4297013991 cites W2965539553 @default.
• W4297013991 cites W2966998200 @default.
• W4297013991 cites W3000745443 @default.
• W4297013991 cites W3029885622 @default.
• W4297013991 cites W3033585737 @default.
• W4297013991 cites W3072257851 @default.
• W4297013991 cites W3119176982 @default.
• W4297013991 cites W3179035963 @default.
• W4297013991 cites W3184800761 @default.
• W4297013991 cites W3194100367 @default.
• W4297013991 cites W4225854422 @default.
• W4297013991 doi "https://doi.org/10.1016/j.xops.2022.100226" @default.
• W4297013991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36339948" @default.
• W4297013991 hasPublicationYear "2023" @default.
• W4297013991 type Work @default.
• W4297013991 citedByCount "1" @default.
• W4297013991 countsByYear W42970139912023 @default.
• W4297013991 crossrefType "journal-article" @default.
• W4297013991 hasAuthorship W4297013991A5003286037 @default.
• W4297013991 hasAuthorship W4297013991A5027369181 @default.
• W4297013991 hasAuthorship W4297013991A5031536941 @default.
• W4297013991 hasAuthorship W4297013991A5034114376 @default.
• W4297013991 hasAuthorship W4297013991A5035588405 @default.
• W4297013991 hasAuthorship W4297013991A5039099781 @default.
• W4297013991 hasAuthorship W4297013991A5050143121 @default.
• W4297013991 hasAuthorship W4297013991A5061263607 @default.
• W4297013991 hasAuthorship W4297013991A5064919549 @default.
• W4297013991 hasAuthorship W4297013991A5076869667 @default.
• W4297013991 hasBestOaLocation W42970139911 @default.
• W4297013991 hasConcept C118487528 @default.
• W4297013991 hasConcept C126322002 @default.
• W4297013991 hasConcept C134018914 @default.
• W4297013991 hasConcept C2778257484 @default.
• W4297013991 hasConcept C2778313320 @default.
• W4297013991 hasConcept C2779829184 @default.
• W4297013991 hasConcept C2780886150 @default.
• W4297013991 hasConcept C44249647 @default.
• W4297013991 hasConcept C555293320 @default.
• W4297013991 hasConcept C67761136 @default.
• W4297013991 hasConcept C71924100 @default.
• W4297013991 hasConceptScore W4297013991C118487528 @default.
• W4297013991 hasConceptScore W4297013991C126322002 @default.
• W4297013991 hasConceptScore W4297013991C134018914 @default.
• W4297013991 hasConceptScore W4297013991C2778257484 @default.
• W4297013991 hasConceptScore W4297013991C2778313320 @default.
• W4297013991 hasConceptScore W4297013991C2779829184 @default.
• W4297013991 hasConceptScore W4297013991C2780886150 @default.
• W4297013991 hasConceptScore W4297013991C44249647 @default.
• W4297013991 hasConceptScore W4297013991C555293320 @default.
• W4297013991 hasConceptScore W4297013991C67761136 @default.
• W4297013991 hasConceptScore W4297013991C71924100 @default.
• W4297013991 hasIssue "1" @default.
• W4297013991 hasLocation W42970139911 @default.
• W4297013991 hasLocation W42970139912 @default.
• W4297013991 hasLocation W42970139913 @default.
• W4297013991 hasLocation W42970139914 @default.
• W4297013991 hasOpenAccess W4297013991 @default.
• W4297013991 hasPrimaryLocation W42970139911 @default.
• W4297013991 hasRelatedWork W2037565925 @default.
• W4297013991 hasRelatedWork W2097959988 @default.

• next